Collaborative Arrangement, Rights And Obligations, Aggregate Upfront Payments Due Upon Execution

No definition available.

Name:	mrk_CollaborativeArrangementRightsAndObligationsAggregateUpfrontPaymentsDueUponExecution
Namespace Prefix:	mrk_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Collaborative Arrangement, Rights And Obligations, Aggregate Upfront Payments Due Upon Lapse Of Time

+ References

No definition available.

+ Details

Name:	mrk_CollaborativeArrangementRightsAndObligationsAggregateUpfrontPaymentsDueUponLapseOfTime
Namespace Prefix:	mrk_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Collaborative Arrangement, Rights And Obligations, Liable Contracted Portion Amount Of Research And Development Expenses To Incur Costs For

+ References

No definition available.

+ Details

Name:	mrk_CollaborativeArrangementRightsAndObligationsLiableContractedPortionAmountOfResearchAndDevelopmentExpensesToIncurCostsFor
Namespace Prefix:	mrk_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Collaborative Arrangement, Rights And Obligations, Liable Contracted Portion Amount Of Research And Development Expenses To Incur Costs For, Percentage

+ References

No definition available.

+ Details

Name:	mrk_CollaborativeArrangementRightsAndObligationsLiableContractedPortionAmountOfResearchAndDevelopmentExpensesToIncurCostsForPercentage
Namespace Prefix:	mrk_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Contingent Milestone Payments, Per Product

+ References

No definition available.

+ Details

Name:	mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentMilestonePaymentsPerProduct
Namespace Prefix:	mrk_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Collaborative Arrangement, Rights And Obligations, Number Of Antibody Drug Conjugates

+ References

No definition available.

+ Details

Name:	mrk_CollaborativeArrangementRightsAndObligationsNumberOfAntibodyDrugConjugates
Namespace Prefix:	mrk_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Collaborative Arrangement, Rights And Obligations, Refundable Upfront Payments

+ References

No definition available.

+ Details

Name:	mrk_CollaborativeArrangementRightsAndObligationsRefundableUpfrontPayments
Namespace Prefix:	mrk_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Collaborative Arrangement, Rights And Obligations, Royalty Percentage On Sales

+ References

No definition available.

+ Details

Name:	mrk_CollaborativeArrangementRightsAndObligationsRoyaltyPercentageOnSales
Namespace Prefix:	mrk_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Proceeds From Upfront Payment, Cash

+ References

No definition available.

+ Details

Name:	mrk_ProceedsFromUpfrontPaymentCash
Namespace Prefix:	mrk_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	srt_CounterpartyNameAxis=mrk_DaiichiSankyoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=mrk_IfinatamabDeruxtecanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=mrk_PatritumabDeruxtecanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=mrk_RaludotatugDeruxtecanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaborative Arrangements - Daiicho Sankyo - Narrative (Details) - Daiichi Sankyo - Collaborative Arrangement, Transaction with Party to Collaborative Arrangement $ in Millions	12 Months Ended
	Dec. 31, 2024 USD ($)	Oct. 31, 2025 USD ($)	Oct. 31, 2024 USD ($)	Dec. 31, 2023 USD ($) candidate
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of antibody drug conjugates obtained right and obligations \| candidate				3
Aggregate upfront payments due upon execution in collaborative arrangement				$ 4,000
Refundable upfront payments in collaborative arrangement				1,000
Maximum aggregate contingent milestone payments, per product, in collaborative arrangement				$ 5,500
Sales based royalty percentage	5.00%			5.00%
Upfront cash payment	$ 170
Ifinatamab Deruxtecan
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Refundable upfront payments in collaborative arrangement				$ 500
Patritumab Deruxtecan
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Refundable upfront payments in collaborative arrangement				$ 500
Aggregate upfront payments due upon lapse of time in collaborative arrangement			$ 750
Raludotatug Deruxtecan
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Aggregate upfront payments due upon lapse of time in collaborative arrangement		$ 750
Liable contracted portion of research and development expenses to incur costs for in collaborative arrangement, percentage				75.00%
Liable contracted portion of research and development expenses to incur costs for in collaborative arrangement				$ 2,000